References
1. Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156 (2): p. 477-491 e1.
2. Schlachterman, A., et al., Current and future treatments for hepatocellular carcinoma. World Journal of Gastroenterology, 2015.21 (28): p. 8478-8491.
3. Bruix, J., G.J. Gores, and V. Mazzaferro, Hepatocellular carcinoma: clinical frontiers and perspectives. Gut, 2014.63 (5): p. 844-855.
4. Raoul, J.L., et al., Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence.Cancer Treat Rev, 2019. 72 : p. 28-36.
5. Zhao, G.S., et al., 350-560 mum gelatin sponge particles combined with transcatheter arterial chemoembolization for the treatment of elderly hepatocellular carcinoma: The safety and efficacy. Medicine (Baltimore), 2017. 96 (16): p. e6629.
6. Liu, S., et al., Complete remission of diffuse hepatocellular carcinoma in a young adult after GSP-TACE: a case report. World J Surg Oncol, 2014. 12 : p. 300.
7. Ohue, Y. and H. Nishikawa, Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target? Cancer Sci, 2019.110 (7): p. 2080-2089.
8. Nishikawa, H. and S. Sakaguchi, Regulatory T cells in tumor immunity. International Journal of Cancer, 2010. 127 (4): p. 759-767.
9. Tanaka, A. and S. Sakaguchi, Targeting Treg cells in cancer immunotherapy. Eur J Immunol, 2019. 49 (8): p. 1140-1146.
10. Curiel, T.J., et al., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004. 10 (9): p. 942-9.
11. Burrel, M., et al., Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.Journal of Hepatology, 2012. 56 (6): p. 1330-1335.
12. Meyer, T., et al., Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.Lancet Gastroenterology & Hepatology, 2017. 2 (8): p. 565-575.
13. Xia, J.L., et al., Study of severe and rare complications of transarterial chemoembolization (TACE) for liver cancer. European Journal of Radiology, 2006. 59 (3): p. 407-412.
14. Liu, Y., et al., Trans-arterial p53-gene-embolization with gelatin sponge microparticles for hepatocellular carcinoma with BCLC stage B: single-center experience. Cell Biochem Biophys, 2015.71 (1): p. 99-104.
15. Zhou, J., et al., Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience. J Cancer Res Ther, 2017. 13 (5): p. 767-772.
16. Li, C., et al., A retrospective analysis of the efficacy of microparticle-mediated chemoembolization in liver metastases arising from gastrointestinal tumors. J Cancer Res Ther, 2017. 13 (4): p. 642-646.
17. Zhang, H.R., Z.Z. Jiang, and L.Y. Zhang, Dual effect of T helper cell 17 (Th17) and regulatory T cell (Treg) in liver pathological process: From occurrence to end stage of disease. International Immunopharmacology, 2019. 69 : p. 50-59.
18. Yang, X.H., et al., Increase of CD4(+) CD25(+) regulatory T-cells in the liver of patients with hepatocellular carcinoma. Journal of Hepatology, 2006. 45 (2): p. 254-262.
19. Kiniwa, Y., et al., CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res, 2007.13 (23): p. 6947-58.
20. Shi, C., et al., CD4(+) CD25(+) regulatory T cells promote hepatocellular carcinoma invasion via TGF-beta1-induced epithelial-mesenchymal transition. Onco Targets Ther, 2019.12 : p. 279-289.
21. Gao, Q., et al., Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. Journal of Clinical Oncology, 2007.25 (18): p. 2586-2593.
22. Morse, M.A., et al., Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther, 2002. 2 (8): p. 827-34.
23. Salmaninejad, A., et al., PD-1/PD-L1 pathway: Basic biology and role in cancer immunotherapy. J Cell Physiol, 2019.234 (10): p. 16824-16837.
24. Seidel, J.A., A. Otsuka, and K. Kabashima, Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol, 2018. 8 : p. 86.
25. Gao, Q., et al., Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res, 2009. 15 (3): p. 971-9.
26. Hato, T., et al., Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions. Hepatology, 2014.60 (5): p. 1776-82.